http://www.biohouston.org BioHouston Release RSS feed. . Copyright 2005, BioHouston Tendenci Membership Management Software by Schipul - The Web Marketing Company en-us noemail@biohouston.org Wed, 08 Sep 2010 04:01:59 GMT Release http://www.biohouston.org/en/rel/506/ With the backing of Novo A/S, Irving, TX-based Reata Pharmaceuticals has raised a whopping $78 million round to finance a final pivotal program for a new therapy for chronic kidney disease and Type 2 diabetes. The new money brings Reata's total venture funding to $180 million. Reata's eggs have been clustered in the bardoxolone basket, a drug which activates the Nrf2 gene and improves the filtration rate of the kidneys, a physical signpost that deteriorates quickly in the face of CKD or diabetes. As Reata CEO Warren Huff explained to FierceBiotech early this year, the FDA has indicated that it will accept the results of an ongoing Phase IIb trial as pivotal, with a confirmatory Phase III study leading to a possible approval as early as 2012. The 78 (million) takes us to an NDA filing, Huff tells FierceBiotech today. The CEO adds that Novo A/S and its other big investor, CPMG, got a look at the six-month data from the IIb trial--the primary endpoint--before pulling the... http://www.biohouston.org/en/rel/506/ noemail@biohouston.org Mon, 12 Jul 2010 19:00:00 GMT